Effective Dose of Ramosetron for Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Patients

Abstract EN

Background.

Postoperative nausea and vomiting (PONV) are common adverse events with an incidence of up to 80% in high-risk patients.

Ramosetron, a selective 5-HT3 receptor antagonist, is widely used to prevent PONV.

The purpose of this study was to evaluate the effective dose of ramosetron for the prevention of PONV in high-risk patients.

Methods.

Fifty-one patients were randomly allocated to 3 groups and were administered ramosetron 0.3 mg (group A), 0.45 mg (group B), or 0.6 mg (group C), at the end of their surgery.

The episodes of PONV were assessed 1, 6, 24, and 48 hours after the injection and all the adverse events were observed.

Results.

The complete response rate in the postoperative period 6–24 hours after the anesthesia was higher in group C than in group A: 93% versus 44%.

Group C’s experience score of Rhodes index was lower than group A’s: 0.81 ± 2.56 versus 3.94 ± 5.25.

No adverse drug reaction could be observed in all groups.

Conclusions.

The effective dose of ramosetron to be injected for the near-complete prophylaxis of PONV 6 to 24 hours after surgery in high-risk patients is a 0.6 mg bolus injection at the end of the surgery.